221 related articles for article (PubMed ID: 27279560)
1. Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma.
Kato T; Lee D; Wu L; Patel P; Young AJ; Wada H; Hu HP; Ujiie H; Kaji M; Kano S; Matsuge S; Domen H; Kaga K; Matsui Y; Kanno H; Hatanaka Y; Hatanaka KC; Matsuno Y; de Perrot M; Yasufuku K
Int J Oncol; 2016 Aug; 49(2):448-56. PubMed ID: 27279560
[TBL] [Abstract][Full Text] [Related]
2. SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
Kato T; Lee D; Wu L; Patel P; Young AJ; Wada H; Hu HP; Ujiie H; Kaji M; Kano S; Matsuge S; Domen H; Kanno H; Hatanaka Y; Hatanaka KC; Kaga K; Matsui Y; Matsuno Y; De Perrot M; Yasufuku K
Int J Oncol; 2016 Dec; 49(6):2411-2420. PubMed ID: 27840913
[TBL] [Abstract][Full Text] [Related]
3. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs dysregulation in human malignant pleural mesothelioma.
Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
[TBL] [Abstract][Full Text] [Related]
5. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
Suraokar MB; Nunez MI; Diao L; Chow CW; Kim D; Behrens C; Lin H; Lee S; Raso G; Moran C; Rice D; Mehran R; Lee JJ; Pass HI; Wang J; Momin AA; James BP; Corvalan A; Coombes K; Tsao A; Wistuba II
Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
[TBL] [Abstract][Full Text] [Related]
7. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.
Mogi A; Koga K; Aoki M; Hamasaki M; Uesugi N; Iwasaki A; Shirakusa T; Tamura K; Nabeshima K
Virchows Arch; 2013 Jan; 462(1):83-93. PubMed ID: 23187830
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
9. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
Linton A; Cheng YY; Griggs K; Schedlich L; Kirschner MB; Gattani S; Srikaran S; Chuan-Hao Kao S; McCaughan BC; Klebe S; van Zandwijk N; Reid G
Br J Cancer; 2014 Jan; 110(2):510-9. PubMed ID: 24327015
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R
Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249
[TBL] [Abstract][Full Text] [Related]
11. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
[TBL] [Abstract][Full Text] [Related]
12. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
[TBL] [Abstract][Full Text] [Related]
13. The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma.
Elshazley M; Sato M; Hase T; Yamashita R; Yoshida K; Toyokuni S; Ishiguro F; Osada H; Sekido Y; Yokoi K; Usami N; Shames DS; Kondo M; Gazdar AF; Minna JD; Hasegawa Y
Int J Cancer; 2012 Dec; 131(12):2820-31. PubMed ID: 22510946
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients.
Kato T; Wada H; Patel P; Hu HP; Lee D; Ujiie H; Hirohashi K; Nakajima T; Sato M; Kaji M; Kaga K; Matsui Y; Tsao MS; Yasufuku K
Lung Cancer; 2016 Feb; 92():53-61. PubMed ID: 26775597
[TBL] [Abstract][Full Text] [Related]
15. CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.
Komiya E; Ohnuma K; Yamazaki H; Hatano R; Iwata S; Okamoto T; Dang NH; Yamada T; Morimoto C
Biochem Biophys Res Commun; 2014 May; 447(4):609-15. PubMed ID: 24747072
[TBL] [Abstract][Full Text] [Related]
16. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
Mairinger FD; Walter RF; Ting S; Vollbrecht C; Kollmeier J; Griff S; Hager T; Mairinger T; Christoph DC; Theegarten D; Schmid KW; Wohlschlaeger J
Future Oncol; 2014 May; 10(6):995-1005. PubMed ID: 24941985
[TBL] [Abstract][Full Text] [Related]
17. Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
Horio M; Sato M; Takeyama Y; Elshazley M; Yamashita R; Hase T; Yoshida K; Usami N; Yokoi K; Sekido Y; Kondo M; Toyokuni S; Gazdar AF; Minna JD; Hasegawa Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3(Suppl 3):S634-45. PubMed ID: 22086445
[TBL] [Abstract][Full Text] [Related]
18. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
Reid G; Pel ME; Kirschner MB; Cheng YY; Mugridge N; Weiss J; Williams M; Wright C; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; Brahmbhatt H; MacDiarmid JA; van Zandwijk N
Ann Oncol; 2013 Dec; 24(12):3128-35. PubMed ID: 24148817
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]